Raffit Hassan Selected Research

Exotoxins

11/2014	Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen 125.
7/2012	Recombinant immunotoxin engineered for low immunogenicity and antigenicity by identifying and silencing human B-cell epitopes.
6/2011	Pentostatin plus cyclophosphamide safely and effectively prevents immunotoxin immunogenicity in murine hosts.
5/2010	Initial characterization of an immunotoxin constructed from domains II and III of cholera exotoxin.
12/2006	Characterization of the B cell epitopes associated with a truncated form of Pseudomonas exotoxin (PE38) used to make immunotoxins for the treatment of cancer patients.
5/2004	Cytotoxic activity of the recombinant anti-mesothelin immunotoxin, SS1(dsFv)PE38, towards tumor cell lines established from ascites of patients with peritoneal mesotheliomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raffit Hassan Research Topics

Disease

91	Neoplasms (Cancer) 05/2024 - 11/2002
56	Mesothelioma 05/2024 - 11/2002
29	Malignant Mesothelioma 01/2022 - 06/2004
16	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 11/2002
8	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 05/2005
8	Lung Neoplasms (Lung Cancer) 01/2022 - 03/2007
7	Disease Progression 01/2022 - 06/2010
7	Adenocarcinoma 01/2020 - 06/2004
7	Adenocarcinoma of Lung 01/2020 - 03/2007
5	Neoplasm Metastasis (Metastasis) 01/2023 - 08/2005
4	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2022 - 03/2007
4	Thymoma (Thymic Carcinoma) 10/2019 - 11/2016
4	Carcinoma (Carcinomatosis) 04/2017 - 05/2007
3	Capillary Leak Syndrome 01/2023 - 01/2013
3	Hairy Cell Leukemia 10/2013 - 12/2006
2	Melanoma (Melanoma, Malignant) 05/2024 - 07/2012
2	Ascites 01/2023 - 05/2004
2	Pneumonia (Pneumonitis) 01/2022 - 02/2021
2	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 01/2022 - 01/2018
2	Leukemia 06/2014 - 10/2007
2	Squamous Cell Carcinoma (Epidermoid Carcinoma) 03/2007 - 11/2002
2	Ovarian Epithelial Carcinoma 09/2005 - 05/2005
1	Basal Cell Carcinoma (Rodent Ulcer) 05/2024
1	Renal Cell Carcinoma (Grawitz Tumor) 05/2024
1	Sepsis (Septicemia) 01/2022
1	Renal Insufficiency (Renal Failure) 01/2022
1	Atrial Fibrillation 01/2022
1	Arthrogryposis renal dysfunction cholestasis syndrome 01/2022
1	Neutropenia 01/2022
1	Liver Failure 01/2022
1	Fever (Fevers) 02/2021
1	Chills 02/2021
1	Carcinogenesis 12/2020

Drug/Important Bio-Agent (IBA)

67	MesothelinIBA 01/2023 - 11/2002
42	Immunotoxins (Immunotoxin)IBA 01/2023 - 11/2002
17	Monoclonal AntibodiesIBA 01/2018 - 05/2004
15	Proteins (Proteins, Gene)FDA Link 05/2024 - 05/2005
13	AntigensIBA 01/2023 - 10/2007
10	AntibodiesIBA 01/2023 - 05/2005
9	amatuximabIBA 01/2018 - 12/2007
8	Pemetrexed (MTA)FDA Link 01/2022 - 09/2011
7	Membrane Proteins (Integral Membrane Proteins)IBA 01/2023 - 08/2005
7	Biomarkers (Surrogate Marker)IBA 01/2023 - 04/2012
7	Differentiation AntigensIBA 01/2020 - 06/2004
7	SS1(dsFv)PE38IBA 04/2016 - 11/2002
6	Cisplatin (Platino)FDA LinkGeneric 01/2021 - 09/2011
6	Membrane Glycoproteins (Membrane Glycoprotein)IBA 05/2015 - 11/2002
6	ExotoxinsIBA 11/2014 - 05/2004
5	EpitopesIBA 01/2023 - 09/2005
5	Immune Checkpoint InhibitorsIBA 01/2022 - 12/2016
5	LMB-100IBA 11/2020 - 03/2017
5	Immunoconjugates (Immunoconjugate)IBA 01/2020 - 01/2011
4	PlatinumIBA 01/2022 - 01/2018
4	Surface Antigens (Surface Antigen)IBA 11/2020 - 01/2006
4	avelumabIBA 10/2019 - 11/2016
4	Bacterial ToxinsIBA 03/2016 - 02/2010
3	anetumab ravtansineIBA 01/2022 - 12/2016
3	AsbestosIBA 12/2020 - 01/2016
3	B7-H1 AntigenIBA 01/2020 - 01/2019
3	Pentostatin (Nipent)FDA LinkGeneric 06/2014 - 06/2011
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2014 - 06/2011
3	VaccinesIBA 06/2014 - 02/2012
3	Paclitaxel (Taxol)FDA LinkGeneric 02/2010 - 08/2006
3	Tumor Biomarkers (Tumor Markers)IBA 07/2006 - 06/2004
3	ParaffinIBA 12/2005 - 11/2002
3	Formaldehyde (Formol)FDA Link 12/2005 - 11/2002
2	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2020
2	Chimeric Antigen ReceptorsIBA 01/2023 - 01/2022
2	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2011
2	olaparibIBA 10/2021 - 01/2020
2	NivolumabIBA 01/2021 - 01/2020
2	DNA (Deoxyribonucleic Acid)IBA 12/2020 - 01/2020
2	pembrolizumabIBA 11/2020 - 01/2020
2	130-nm albumin-bound paclitaxelIBA 01/2020 - 03/2017
2	LigandsIBA 01/2019 - 11/2016
2	Histone Deacetylase InhibitorsIBA 10/2017 - 09/2011
2	Neoplasm Antigens (Tumor Antigens)IBA 12/2016 - 05/2005
2	T-Lymphocyte Epitopes (Epitopes, T Lymphocyte)IBA 12/2015 - 06/2014
2	Immunoglobulin G (IgG)IBA 02/2015 - 05/2005
2	Immunoglobulin Variable RegionIBA 11/2014 - 12/2006
2	Antineoplastic Agents (Antineoplastics)IBA 06/2014 - 01/2006
2	Cancer VaccinesIBA 06/2014 - 03/2012
2	Neutralizing AntibodiesIBA 01/2013 - 06/2011
2	Messenger RNA (mRNA)IBA 11/2012 - 03/2007
2	Gemcitabine FDA Link 01/2012 - 12/2007
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2023
1	Polysaccharides (Glycans)IBA 01/2023
1	Vinorelbine (Navelbine)FDA LinkGeneric 01/2022
1	UbiquitinIBA 01/2021
1	IpilimumabIBA 01/2021
1	Interleukin-12 (IL 12)IBA 12/2020
1	Interleukin-10 (Interleukin 10)IBA 12/2020
1	Interleukin-3 (Interleukin 3)IBA 12/2020
1	CreatinineIBA 11/2020

Therapy/Procedure

45	Therapeutics 01/2023 - 11/2002
14	Immunotherapy 01/2022 - 08/2005
13	Drug Therapy (Chemotherapy) 01/2022 - 12/2007
2	Radiotherapy 01/2020 - 01/2018
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2023
1	Intravenous Administration 01/2022